Phenotyping patients with ischaemic heart disease at risk of developing heart failure: an analysis of the HOMAGE trial.
Fiche publication
Date publication
novembre 2023
Journal
ESC heart failure
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick
Tous les auteurs :
Santos-Ferreira D, Diaz SO, Ferreira JP, Girerd N, Pellicori P, Mariottoni B, Cosmi F, Hazebroek M, Verdonschot JAJ, Cuthbert J, Petutschnigg J, Heymans S, Staessen JA, Pieske B, Edelmann F, Clark AL, Rossignol P, Fontes-Carvalho R, Cleland JGF, Zannad F
Lien Pubmed
Résumé
We aim to characterize the clinical and proteomic profiles of patients at risk of developing heart failure (HF), with and without coronary artery disease (CAD) or prior myocardial infarction (MI).
Mots clés
Coronary artery disease, Heart failure, Myocardial infarction, Proteomics, Spironolactone
Référence
ESC Heart Fail. 2023 11 8;: